Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 27 of 30
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
NCT00606801
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
NCT00473720
The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
NCT00580853
Effective Treatment of Hepatitis C in Substance Users
NCT00633243
Examining New Diagnostic Tests for Acute Kidney Injury After Heart Surgery
NCT00774137
Do Treatments for Smoking Cessation Affect Alcohol Drinking?
NCT00580645
Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban
NCT00511134
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
NCT00461851
The Effect of Plasma Osmolality on Brain Glutamate
NCT00611741
Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
NCT00567320
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
NCT00461773
Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)
NCT00763178
The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women
NCT00421408
Effect of Music Therapy on Patients Undergoing Intravitreal Injections
NCT00702039
Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
NCT00417612
Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.
NCT00593125
Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
NCT00616746
GABA-glutamate Interactions and Psychosis
NCT00611572
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
NCT00571961
Cranberry for UTI Prevention in Residents of Long Term Care Facilities
NCT00596635
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers
NCT00633256
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
NCT00411788
Recovery Guide Intervention for Recurrent Psychiatric Hospitalization
NCT00400166
A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma
NCT00411762
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
NCT00367991
Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities
NCT00589095
Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD
NCT00585299
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
NCT00523718
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
NCT00463346
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes
NCT00378508
Why Are Patients With Absence Seizures Absent? A Brain Imaging Study
NCT00393666
Safety of Sports for Patients With Implantable Cardioverter-Defibrillators
NCT00637754
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
NCT00846521
Simulation Training for Ultrasound Guided Central Venous Catheter Insertion
NCT00919308
Modafinil, Sleep, and Cognition in Cocaine Dependence
NCT00582491
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
NCT00402714
Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence
NCT00548275
Family History Study of Alcohol Consumption Using Memantine
NCT00630955
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
NCT00335829
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
NCT00486330
Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma
NCT00611624
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
NCT00303888
Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse
NCT00585754
Specialized Treatment Early in Psychosis (STEP)
NCT00309452
Tele-HF: Yale Heart Failure Telemonitoring Study
NCT00303212
Glycine vs Placebo for the Schizophrenia Prodrome
NCT00291226
Dialysate Sodium Individualization in Hemodialysis
NCT00259714
Sex Hormones and Orthostatic Tolerance
NCT01153581
Transcranial Magnetic Stimulation for "Voices"
NCT00308997
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
NCT00402415
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.